Wai Yuen Tong Medicine Holdings Limited 0897
HKEX · Hong Kong SAR China · Health Technology
HKD 0.3750+0.01 (+1.35%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Summit Therapeutics (SMMT) is back in focus after AstraZeneca agreed to invest about US$2 billion through convertible preferred stock and entered a non exclusive clinical collaboration built around ivonescimab combinations. Summit Therapeutics’ share price has been volatile, with a 6.9% 7 day share price return and a 14.3% 30 day share price return. However, the year to date share price return is down 4.7%, while the 1 year total shareholder return has declined 22.1%. This follows very large...
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents).
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.